Published in Clin Med Res on February 10, 2016
Recurrent Graves' hyperthyroidism after prolonged radioiodine-induced hypothyroidism. Ther Adv Endocrinol Metab (2017) 0.75
Graves' disease. N Engl J Med (2000) 3.50
The epidemiology of thyroid disease. Br Med Bull (2011) 2.20
High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab (2002) 1.78
The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Clin Endocrinol (Oxf) (1997) 1.54
Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab (2001) 1.45
A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab (2012) 1.43
Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab (2010) 1.35
Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev (2012) 1.34
Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab (2000) 1.22
Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Am J Med (1995) 0.86
Transient hypothyroidism after iodine-131 treatment of Graves' disease. Thyroidology (1989) 0.84
Transient hypothyroidism after iodine-131 therapy for Grave's disease. J Nucl Med (1995) 0.84
Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves' disease. Clin Endocrinol (Oxf) (1998) 0.84
A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism. BMC Nucl Med (2001) 0.82
Influence of propylthiouracil and methimazole pre-treatment on the outcome of iodine-131 therapy in hyperthyroid patients with Graves' disease. J Int Med Res (2009) 0.81
Thyroid stunning in vivo and in vitro. Nucl Med Commun (2005) 0.81
Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy. Ann Nucl Med (2005) 0.80
Time interval between the last dose of propylthiouracil and I-131 therapy influences cure rates in hyperthyroidism caused by Graves' disease. Clin Nucl Med (1998) 0.78